These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms. Yasui-Furukori N; Kondo T; Ishida M; Furukori H; Suzuki A; Kaneko S; Inoue M; Otani K Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):53-7. PubMed ID: 11853119 [TBL] [Abstract][Full Text] [Related]
25. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol. Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941 [TBL] [Abstract][Full Text] [Related]
26. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics. Perry PJ; Miller DD; Arndt SV; Smith DA; Holman TL J Clin Psychopharmacol; 1993 Feb; 13(1):46-51. PubMed ID: 8486817 [TBL] [Abstract][Full Text] [Related]
27. Serum prolactin as a correlate of clinical response to haloperidol. Van Putten T; Marder SR; Mintz J J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154 [TBL] [Abstract][Full Text] [Related]
28. Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment. Czobor P; Volavka J Compr Psychiatry; 1996; 37(3):205-15. PubMed ID: 8732588 [TBL] [Abstract][Full Text] [Related]
29. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics. Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444 [TBL] [Abstract][Full Text] [Related]
30. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054 [TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia. Smith RC; Baumgartner R; Shvartsburd A; Ravichandran GK; Vroulis G; Mauldin M Psychopharmacology (Berl); 1985; 85(4):449-55. PubMed ID: 2862652 [TBL] [Abstract][Full Text] [Related]
32. A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Janicak PG; Javaid JI; Sharma RP; Leach A; Dowd S; Davis JM Acta Psychiatr Scand; 1997 Apr; 95(4):343-50. PubMed ID: 9150830 [TBL] [Abstract][Full Text] [Related]
33. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. Piscitelli SC; Frazier JA; McKenna K; Albus KE; Grothe DR; Gordon CT; Rapoport JL J Clin Psychiatry; 1994 Sep; 55 Suppl B():94-7. PubMed ID: 7961584 [TBL] [Abstract][Full Text] [Related]
34. Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. Yasui N; Kondo T; Suzuki A; Otani K; Mihara K; Furukori H; Kaneko S; Inoue Y Int Clin Psychopharmacol; 1999 Mar; 14(2):113-8. PubMed ID: 10220126 [TBL] [Abstract][Full Text] [Related]
35. The Dose Reduction in Schizophrenia (DORIS) Study: a final report. Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126 [TBL] [Abstract][Full Text] [Related]
36. Haloperidol and reduced haloperidol concentrations and psychiatric ratings in schizophrenic patients treated with ascorbic acid. Straw GM; Bigelow LB; Kirch DG J Clin Psychopharmacol; 1989 Apr; 9(2):130-2. PubMed ID: 2566628 [TBL] [Abstract][Full Text] [Related]
37. Plasma drug level and clinical response. Cooper TB; Volavka J; Czobor P J Clin Psychopharmacol; 1992 Apr; 12(2):134-6. PubMed ID: 1573036 [No Abstract] [Full Text] [Related]
38. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients. Hollister LE; Kim DY Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396 [TBL] [Abstract][Full Text] [Related]
39. Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state. Jibiki I; Kubota T; Fujimoto K; Sakamoto H; Hasegawa M; Furuta H; Yamaguchi N Jpn J Psychiatry Neurol; 1993 Sep; 47(3):627-9. PubMed ID: 8301878 [No Abstract] [Full Text] [Related]
40. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]